1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,200 | 1,240 | 19.11. | |
| 1,190 | 1,250 | 19.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | NanoViricides GAAP EPS of -$0.10 | 6 | Seeking Alpha | ||
| Mo | NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position | 187 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter... ► Artikel lesen | |
| Fr | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Fr | NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2 | 377 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 12.11. | NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 472 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 11.11. | NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close | 515 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a... ► Artikel lesen | |
| 10.11. | NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo | 484 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of... ► Artikel lesen | |
| 05.11. | NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT | 473 | ACCESS Newswire | NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT / ACCESS Newswire / November 5, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company")... ► Artikel lesen | |
| 03.11. | NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd | 394 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 29.10. | Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive | 529 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve... ► Artikel lesen | |
| 27.10. | NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 | 572 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the... ► Artikel lesen | |
| 22.10. | In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides | 476 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 20.10. | A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus | 491 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV-387 has shown strong... ► Artikel lesen | |
| 15.10. | NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses | 445 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains... ► Artikel lesen | |
| 01.10. | NanoViricides verlängert Verträge mit Führungskräften und passt Kreditlinie an | 5 | Investing.com Deutsch | ||
| 01.10. | NANOVIRICIDES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 30.09. | NanoViricides, Inc. Has Filed its Annual Report | 680 | ACCESS Newswire | Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30... ► Artikel lesen | |
| 29.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 9 | SEC Filings | ||
| 09.09. | NanoViricides to Present at the Life Science Executive Partnering Congress in Boston on September 17, 2025 | 811 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 18.08. | NanoViricides: A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials | 571 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 23,300 | +4,25 % | Formycon: "Entwicklungen verliefen planmäßig" | Formycon hat am Donnerstag die Geschäftsentwicklung für die ersten neun Monate 2025 vorgelegt und bestätigt die Jahresprognose. Der Konzernumsatz sank auf 19,5 Millionen Euro nach 41,1 Millionen Euro... ► Artikel lesen | |
| ONTO INNOVATION | 113,00 | +4,63 % | Onto Innovation completes acquisition of Semilab product lines | ||
| GAUZY | 2,040 | -13,56 % | Gauzy Shares Tumble 14% As Company Delays Q3 Earnings Amid French Insolvency Proceedings | ||
| SOLESENCE | 1,950 | +6,56 % | SOLESENCE, INC. - 10-Q, Quarterly Report | ||
| KOPIN | 1,953 | -6,38 % | Why Kopin Stock Slipped Today | ||
| GOMSPACE | 1,336 | -1,62 % | GomSpace Group AB: GomSpace Reports Strong Q3 Performance with continued Growth and Profitability | 94% year-on-year revenue growth and positive EBITDA and EBIT support upgraded full-year guidance, and GomSpace's significantly improved balance sheet strengthens its position to capture current market... ► Artikel lesen | |
| VEECO INSTRUMENTS | 24,000 | +0,84 % | Veeco Instruments Inc.: Veeco Reports Third Quarter 2025 Financial Results | Third Quarter 2025 Highlights: Revenue of $165.9 million, compared with $184.8 million in the same period last yearGAAP net income of $10.6 million, or $0.17 per diluted share, compared with $22.0... ► Artikel lesen | |
| ACACIA RESEARCH | 2,900 | -1,36 % | Acacia Research Non-GAAP EPS of -$0.01 beats by $0.13, revenue of $59.4M beats by $21.4M | ||
| NVE | 50,50 | 0,00 % | Dividendenbekanntmachungen (03.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECOAGRO SA LU0584671464 0,1748 USD 0,1515 EUR AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR AON PLC IE00BLP1HW54 0... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,575 | 0,00 % | ADVANCE ZINCTEK LIMITED: FDA Inspection Update | ||
| LAMPETIA | 0,092 | 0,00 % | EQS-News: Lampetia AG: Halbjahresfinanzbericht auf neuer Webseite | EQS-News: Lampetia AG
/ Schlagwort(e): Halbjahresbericht
LAMPETIA AG: Halbjahresfinanzbericht auf neuer Webseite
30.09.2025 / 19:51 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| NANOFOCUS | 1,800 | 0,00 % | HV-Termine: Hauptversammlungen bei bioXXmed, Borussia Dortmund, CureVac, elexxion, Nanofocus, NSI Asset, OTRS | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| RIBER | 3,010 | -0,50 % | 2025 first-half earnings: RIBER confirms the rollout of its roadmap and its annual outlook | 2025 first-half earnings: RIBER confirms the rollout of its roadmap and its annual outlook. Half-year revenues and earnings, particularly marked by seasonal activity patterns. Order book of €27.7m... ► Artikel lesen | |
| DOTZ NANO | 0,022 | +7,32 % | DOTZ NANO LIMITED: Extension of Maturity Date for Convertible Notes | ||
| ZENTEK | 0,630 | 0,00 % | Zentek Ltd. - 6-K, Report of foreign issuer |
Das Unternehmen NANOVIRICIDES INC kann der Branche Nanotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.